Ductal Carcinoma
In Situ
407
247. Jackman RJ, Nowels KW, Shepard MJ, et al. Stereotaxic large-core
needle biopsy of 450 nonpalpable breast lesions with surgical cor-
relation in lesions with cancer or atypical hyperplasia.
Radiology
1994;193:91–95.
248. Liberman L, Dershaw DD, Rosen PP, et al. Stereotaxic core biopsy
of breast carcinoma: accuracy at predicting invasion.
Radiology
1995;194:379–381.
249. Burbank F. Stereotactic breast biopsy of atypical ductal hyperplasia
and ductal carcinoma
in situ
lesions: improved accuracy with direc-
tional, vacuum-assisted biopsy.
Radiology
1997;202:843–847.
250. Mendez I, Andreu FJ, Saez E, et al. Ductal carcinoma
in situ
and atypi-
cal ductal hyperplasia of the breast diagnosed at stereotactic core bi-
opsy.
Breast J
2001;7:14–18.
251. Renshaw AA. Predicting invasion in the excision specimen from
breast core needle biopsy specimens with only ductal carcinoma
in
situ
.
Arch Pathol Lab Med
2002;126:39–41.
252. Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of
nonpalpable lesions: determinants of ductal carcinoma
in situ
under-
estimation rates.
Radiology
2001;218:497–502.
253. Tuttle TM, Shamliyan T, Virnig BA, et al. The impact of sentinel
lymph node biopsy and magnetic resonance imaging on important
outcomes among patients with ductal carcinoma
in situ
.
J Natl Cancer
Inst Monogr
2010;2010(41):117–120.
254. Dillon MF, Quinn CM, McDermott EW, et al. Diagnostic accuracy of
core biopsy for ductal carcinoma
in situ
and its implications for surgi-
cal practice.
J Clin Pathol
2006;59:740–743.
255. Dillon MF, Maguire AA, McDermott EW, et al. Needle core biopsy
characteristics identify patients at risk of compromised margins in
breast conservation surgery.
Mod Pathol
2008;21:39–45.
256. Wang HH, Ducatman BS, Eick D. Comparative features of ductal car-
cinoma
in situ
and infiltrating ductal carcinoma of the breast on fine-
needle aspiration biopsy.
Am J Clin Pathol
1989;92:736–740.
257. Willems SM, van Deurzen CH, van Diest PJ. Diagnosis of breast le-
sions: fine-needle aspiration cytology or core needle biopsy? A review.
J Clin Pathol
2012;65:287–292.
258. Sneige N, Singletary SE. Fine-needle aspiration of the breast: diagnos-
tic problems and approaches to surgical management.
Pathol Annu
1994;29(Pt. 1):281–301.
259. Guo HQ, Zhang ZH, Zhao H, et al. Recognizing breast ductal carci-
noma
in situ
on fine-needle aspiration: a diagnostic dilemma.
Diagn
Cytopathol
2013;41:710–715.
260. McKee GT, Tildsley G, Hammond S. Cytologic diagnosis and grading
of ductal carcinoma
in situ
.
Cancer
1999;87:203–209.
261. Lester SC, Bose S, Chen YY, et al. Protocol for the examination of
specimens from patients with ductal carcinoma
in situ
of the breast.
Arch Pathol Lab Med
2009;133:15–25.
262. Saqi A, Osborne MP, Rosenblatt R, et al. Quantifying mammary duct
carcinoma
in situ
: a wild-goose chase?
Am J Clin Pathol
2000;113(5
Suppl. 1):S30–S37.
263. Grin A, Horne G, Ennis M, et al. Measuring extent of ductal carci-
noma
in situ
in breast excision specimens: a comparison of 4 methods.
Arch Pathol Lab Med
2009;133:31–37.
264. Marcotte-Bloch C, Balu-Maestro C, Chamorey E, et al. MRI for the
size assessment of pure ductal carcinoma
in situ
(DCIS): a prospective
study of 33 patients.
Eur J Radiol
2011;77:462–467.
265. Thomas J, Evans A, Macartney J, et al. Radiological and pathological
size estimations of pure ductal carcinoma
in situ
of the breast, speci-
men handling and the influence on the success of breast conserva-
tion surgery: a review of National Surgical Adjuvant Breast Project
(NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma
in
situ
).
Cancer
1995;75:1310–1319.
266. Tavassoli FA, Norris HJ. A comparison of the results of long-term
follow-up for atypical intraductal hyperplasia of the breast.
Cancer
1990;65:518–529.
267. Lagios MD, Westdahl PR, Margolin FR, et al. Duct carcinoma
in situ
.
Relationship of extent of noninvasive disease to the frequency of oc-
cult invasion, multicentricity, lymph node metastases, and short-term
treatment failures.
Cancer
1982;50:1309–1314.
268. Lagios MD. Ductal carcinoma
in situ
: biological and therapeutic im-
plications of classification.
Breast J
1996;2:32–34.
269. Silverstein MJ, Cohlan BF, Gierson ED, et al. Duct carcinoma
in situ
:
227 cases without microinvasion.
Eur J Cancer
1992;28:630–634.
270. Cheatle GL. Benign and malignant changes in duct epithelium of the
breast.
Br J Surg
1920/1921;8:285–306.
222. Visscher DW, Wallis TL, Crissman JD. Evaluation of chromosome
aneuploidy in tissue sections of preinvasive breast carcinomas using
interphase cytogenetics.
Cancer
1996;77:315–320.
223. Sarode VR, Han JS, Morris DH, et al. A comparative analysis of bio-
marker expression and molecular subtypes of pure ductal carcinoma
in situ
and invasive breast carcinoma by image analysis: relationship
of the subtypes with histologic grade, Ki67, p53 overexpression, and
DNA ploidy.
Int J Breast Cancer
2011;2011:217060.
224. Stasik CJ, Davis M, Kimler BF, et al. Grading ductal carcinoma
in situ
of the breast using an automated proliferation index.
Ann Clin Lab Sci
2011;41:122–130.
225. Rakovitch E, Nofech-Mozes S, HannaW, et al. HER2/neu andKi-67 ex-
pression predict non-invasive recurrence following breast-conserving
therapy for ductal carcinoma
in situ
.
Br J Cancer
2012;106:1160–1165.
226. Gandhi A, Holland PA, Knox WF, et al. Evidence of significant apop-
tosis in poorly differentiated ductal carcinoma
in situ
of the breast.
Br
J Cancer
1998;78:788–794.
227. Radford DM, Fair K, Thompson AM, et al. Allelic loss on chro-
mosome 17 in ductal carcinoma
in situ
of the breast.
Cancer Res
1993;53:2947–2950.
228. Alburquerque A, Kennedy S, Bryant B, et al. LOH on chromosome 17p
and 17q in the histologic spectrum of DCIS.
Mod Pathol
1997;10:15A.
229. Lichy JH, Zavar M, Tsai MM, et al. Loss of heterozygosity on chromo-
some 11p15 during histological progression in microdissected ductal
carcinoma of the breast.
Am J Pathol
1998;153:271–278.
230. Chuaqui RF, Zhuang Z, Emmert-Buck MR, et al. Analysis of loss of
heterozygosity on chromosome 11q13 in atypical ductal hyperplasia
and
in situ
carcinoma of the breast.
Am J Pathol
1997;150:297–303.
231. Chen T, Sahin A, Aldaz CM. Deletion map of chromosome 16q in
ductal carcinoma
in situ
of the breast: refining a putative tumor sup-
pressor gene region.
Cancer Res
1996;56:5605–5609.
232. Fujii H, Szumel R, Marsh C, et al. Genetic progression, histological
grade, and allelic loss in ductal carcinoma
in situ
of the breast.
Cancer
Res
1996;56:5260–5265.
233. Stratton MR, Collins N, Lakhani SR, et al. Loss of heterozygosity in
ductal carcinoma
in situ
of the breast.
J Pathol
1995;175:195–201.
234. Radford DM, Phillips NJ, Fair KL, et al. Allelic loss and the progres-
sion of breast cancer.
Cancer Res
1995;55:5180–5183.
235. Munn KE, Walker RA, Varley JM. Frequent alterations of chro-
mosome 1 in ductal carcinoma
in situ
of the breast.
Oncogene
1995;10:1653–1657.
236. Zhuang Z, Merino MJ, Chuaqui R, et al. Identical allelic loss on chro-
mosome 11q13 in microdissected
in situ
and invasive human breast
cancer.
Cancer Res
1995;55:467–471.
237. James LA, Mitchell ELD, Menasce L, et al. Comparative genomic hy-
bridisation of ductal carcinoma
in situ
of the breast: identification of
regions of DNA amplification and deletion in common with invasive
breast carcinoma.
Oncogene
1997;14:1059–1065.
238. Barsky SH, Shao ZM, Bose S. Should DCIS be renamed carcinoma of
the ductal system?
Breast J
1999;5:70–72.
239. Marsh KL, Varley JM. Loss of heterozygosity at chromosome 9p in
ductal carcinoma
in situ
and invasive carcinoma of the breast.
Br J
Cancer
1998;77:1439–1447.
240. Aubele M, Mattis A, Zitzelsberger H, et al. Extensive ductal carcinoma
in situ
with small foci of invasive ductal carcinoma: evidence of genetic
resemblance by CGH.
Int J Cancer
2000;85:82–86.
241. Waldman FM, DeVries S, Chew KL, et al. Chromosomal alterations in
ductal carcinomas
in situ
and their
in situ
recurrences.
J Natl Cancer
Inst
2000;92:313–320.
242. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al. Breast cancer
precursors revisited: molecular features and progression pathways.
Histopathology
2010;57:171–192.
243. Polyak K. Molecular markers for the diagnosis and manage-
ment of ductal carcinoma
in situ
.
J Natl Cancer Inst Monogr
2010;2010(41):210–213.
244. Zhou W, Jirström K, Johansson C, et al. Long-term survival of women
with basal-like ductal carcinoma
in situ
of the breast: a population-
based cohort study.
BMC Cancer
2010;10:653.
245. Burkhardt L, Grob TJ, Hermann I, et al. Gene amplification in
ductal carcinoma
in situ
of the breast.
Breast Cancer Res Treat
2010;123:757–765.
246. Schwartz GF, Solin LJ, Olivotto IA, et al. The Consensus Conference
on the treatment of
in situ
ductal carcinoma of the breast, April 22–25,
1999.
Hum Pathol
2000;31:131–139.
